朗格汉斯细胞组织细胞增生症(Langerhans cell histiocytosis，LCH)是一种罕见的树突细胞和网状细胞系统增生性疾病，目前分为单系统LCH(SS-LCH)和多系统LCH(MS –LCH)。MS-LCH的预后较差，及时有效地干预是患者存活的关键。目前有化学治疗、免疫治疗、造血干细胞移植治疗等多种治疗方案。文章就MS-LCH相关治疗方案的进展进行综述。

　Langerhans cell histiocytosis (LCH) is a rare proliferative disorder of dendritic cells and the reticular cells. It is divided into single-system langerhans cell histiocytosis (SS-LCH) and multi-system langerhans cell system (MS-LCH). MS-LCH has a very poor prognosis. The key of survival is timely and effective treatment. The treatment protocols include chemotherapy, immunotherapy and stem cells transplantation. In this review, the new advances in the treatment of MS-LCH were systemically reviewed.